TABLE 5

Predictors of annual decline of forced expiratory volume in 1 s (FEV1) (mL) from Max0–2.5 to follow-up in multiple linear regression analysis (n=154)

FEV1 estimated decline ΔmL (95% CI)p-value
ΔBMI (Max0–2.5–follow-up)−1.37 (−2.87–0.13)0.072
Age at follow-up−0.30 (−0.61– −0.00)0.052
Female sex7.64 (−1.45–16.72)0.099
≥10 pack-years at follow-up−12.08 (−21.36– −2.80)0.011
Log blood eosinophils at follow-up−18.23 (−32.23– −4.23)0.011
ΔFEV1 mL# (baseline–Max0–2.5)−0.04 (−0.05– −0.03)<0.001
FEV1 % pred# at baseline−0.54 (−0.84– −0.24)<0.001
Not daily ICS user at follow-up−2.98 (−13.36–7.39)0.849
FeNO at follow-up >20 ppb−10.70 (−20.54– −0.86)0.033
Oral steroids during follow-up−7.79 (−16.60–1.02)0.083
  • Max0–2.5: point of highest lung function (FEV1 % pred) during the first 2.5 years after baseline; BMI: body mass index; ICS: inhaled corticosteroids; FeNO: exhaled nitric oxide fraction. #: pre-bronchodilator values; : statistically significant at p<0.05.